(BUSINESS WIRE)--Pfizer Inc announced today that Toviaz™ (fesoterodine fumarate) extended release tablets and the YourWay™ plan (www.ToviazYourWay.com), a comprehensive, customizable support plan for overactive bladder patients, are available in the United States. Toviaz is a once-daily prescription treatment for patients with symptoms of overactive bladder, which include frequent and sudden urges to urinate and wetting accidents. Toviaz works by helping to calm the bladder muscle that causes frequent, sudden urges to urinate.
Overactive bladder affects an estimated 33 million Americans, yet remains under-treated. One possible reason for this is that patients may be embarrassed to discuss their overactive bladder symptoms with a physician and often develop coping strategies, such as planning “escape routes” to restrooms in public places, which allow them to delay seeking treatment.
“Given Pfizer’s long heritage in the overactive bladder market with Detrol and Detrol LA, we understand that experiences and challenges with overactive bladder differ from patient to patient,” said Olivier Brandicourt, president and general manager of Pfizer’s Primary Care Business Unit. “To help address these challenges for both physicians and patients, Pfizer is proud to introduce Toviaz, which offers the flexibility of two efficacious doses to treat patients based on individual need, plus the innovative YourWay program.”
The YourWay plan is a free, simple 12-week program designed to help physicians educate patients about their condition and treatment expectations, and to encourage and empower patients to become more engaged in their treatment. Developed in collaboration with experts in adherence, behavioral change, and patient education and communication, the YourWay plan includes four components:
The basic YourWay plan is offered to patients who receive a Toviaz sample pack or prescription from their doctor. Patients also may enroll in the plan by calling 1-877-796-8792 or visiting www.ToviazYourWay.com.
Participants can choose to receive an added level of customized support from the YourWay plan:
“Behavior change is an important part of overactive bladder treatment, yet many overactive bladder patients don’t receive behavioral intervention,” said Dr. Pamela Ellsworth, associate professor of urology, Warren Alpert Medical School at Brown University and consultant for the YourWay plan. “The YourWay plan is great news for patients because it emphasizes that change doesn’t happen overnight, and can motivate patients with ongoing encouragement, realistic goals and tangible changes they can make each day.”
Toviaz Provides Dosing Flexibility for Physicians, Patients
Toviaz is available in two efficacious doses, 4 mg and 8 mg, allowing dosing flexibility to optimize treatment based on the individual patient response and tolerability. Toviaz was approved by the U.S. Food and Drug Administration in October 2008.
The approval of Toviaz was based on two large 12-week Phase 3 clinical studies that showed once-daily Toviaz can significantly reduce bothersome symptoms for 24 hours – all day and all night. The recommended starting dose of Toviaz is 4 mg once daily. Based upon individual response and tolerability, the dose may be increased to 8 mg once daily. Doses greater than 4 mg are not recommended in patients with severe renal insufficiency or in patients taking a potent CYP3A4 inhibitor; in patients taking a weak or moderate CYP3A4 inhibitor, careful assessment at 4 mg is advised prior to increasing to 8 mg.
Toviaz treats the symptoms of overactive bladder (leaks, strong, sudden urges to go, going too often).
Important Safety Information for Toviaz
If patients have certain stomach problems, glaucoma, or cannot empty their bladder, they should not take Toviaz.
Medicines like Toviaz can cause blurred vision, drowsiness, and decreased sweating. Patients should use caution when driving, doing unsafe tasks, or in especially hot environments, until they know how Toviaz affects them. Drinking alcohol while taking medicines such as Toviaz may cause increased drowsiness.
The most common side effects are dry mouth and constipation.
Toviaz has benefits and risks. There may be other options.
Important Safety Information for Detrol LA
Patients should not take DETROL LA if they have certain types of stomach problems, glaucoma, or cannot empty their bladder. The most common side effect is dry mouth. Other side effects may include headache, constipation, and abdominal pain.
Detrol® LA (tolterodine tartrate extended release capsules) treats the symptoms of overactive bladder (leaks, strong sudden urges to go, going too often).
DETROL LA has benefits and risks. There may be other options.
About Overactive Bladder
Overactive bladder is a treatable medical condition associated with involuntary contractions of the bladder muscle, and is defined by urinary urgency (a sudden compelling desire to pass urine that is difficult to defer) with or without urgency incontinence (the involuntary leakage of any amount of urine, associated with or immediately preceded by urgency), usually with increased daytime urinary frequency and nocturia.
Pfizer Inc: Working together for a healthier world™
Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, more than 80,000 colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.
Sally Beatty, 212-733-6566
Suzanne Harnett, 212-733-8009